May 30, 2016
1 min read
Save

Highlights from Digestive Disease Week 2016: What you need to know

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Digestive Disease Week 2016 recently concluded in San Diego, ending this year’s largest gathering in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Listed below is a sampling of the latest news and research for family and primary care physicians. Here’s what you need to know:

Acetaminophen-induced acute liver injury, acute liver failure occurs more in women

Despite having increased rates of acetaminophen-induced acute liver injury and acute liver failure than men, women did not experience poorer survival outcomes related to these conditions, according to researchers at the University of California, San Francisco. Read more.

Cost per SVR with Harvoni found lower than previously reported

Researchers at Kaiser Permanente determined the cost per sustained virologic response (SVR) with Harvoni for treating chronic hepatitis C genotype 1 was lower than the cost reported for previous regimens. Read more.

Celiac disease not associated with depression in adolescents

Celiac disease was not linked to major depressive disorder in adolescents, according to researchers at the University of Chicago Medical Center. However, most adolescents with celiac disease did have symptoms consistent with the disorder. Read more.

VIDEO: IBS blood test gives physician, patient confidence in diagnosis

Mark Pimentel, MD, of Cedars Sinai Medical Center, discusses the importance of IBScheck, a new blood test for irritable bowel syndrome (IBS). Watch here.

MODIFY: Bezlotoxumab prevents recurrent C. difficile infection in high-risk patients

According to a researcher from Beth Israel Deaconess Medical Center and Harvard Medical School, data from the MODIFY trials showed bezlotoxumab was effective in reducing rates of recurrent Clostridium difficile infection in high-risk patients. Read more.